Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second ...
A 10 ml vial of Sanofi's long-acting insulin Lantus first hit the US market at $34.81 a vial in 2001, according to data from Truven Health Analytics. Since 2014, the last time Sanofi raised the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback